1008-00003 · Client 1008 · Memos & Analysis

memo-misrepresentation-analysis-delaware.docx DOCUMENT Funds

20 / 35 ← → ✕

PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGED ATTORNEY WORK PRODUCT

MEMORANDUM

This memorandum is protected by the attorney-client privilege and the work product doctrine. It is intended solely for the use of Calderwood & Harkness LLP attorneys working on the referenced matter and our client, Lumos Analytics Inc. This memorandum should not be disclosed to any third party without the express prior authorization of the supervising partner.

FROM: Christy Bauer, Associate, Calderwood & Harkness LLP

TO: Omar Siddiqui, Associate; Patricia Dunmore, Partner

DATE: October 17, 2023

RE: Analysis of Potential Fraud and Misrepresentation Claims by Vantage Peak Ventures Fund II, L.P. Against Lumos Analytics Inc. Under Delaware Law

MATTER NO.: 1008-00003

CLIENT: Lumos Analytics Inc.

I. EXECUTIVE SUMMARY

This memorandum evaluates the merits, risks, and potential defenses available to our client, Lumos Analytics Inc. ("Lumos" or the "Company"), in connection with fraud and misrepresentation claims that Vantage Peak Ventures Fund II, L.P. ("Vantage Peak" or "VPV") may assert against Lumos arising from its $3,500,000 Post-Money Simple Agreement for Future Equity ("SAFE") executed on September 12, 2023.

The catalyst for this analysis is Vantage Peak's October 15, 2023 request for a return of its invested funds, followed by a formal withdrawal on October 18, 2023. On that date, Vantage Peak's counsel, Whitfield Harte & Associates LLP, transmitted a demand letter alleging that Lumos's August 2023 investor pitch materials contained a material misrepresentation regarding the readiness of Lumos's core technology product. Specifically, Whitfield Harte alleges that Lumos represented its machine-learning compliance scoring module, Prism Core v2.0, as "beta-ready by Q4 2023," and that this representation was materially false or misleading in light of a subsequent validation report prepared by Peralta IP Consulting LLC, dated October 9, 2023, which showed the module achieved only 61% accuracy against a required benchmark target of 92%.

After reviewing the relevant factual record, the applicable provisions of the executed SAFE, and the governing Delaware common law, I conclude as follows:

Lumos has colorable defenses under both the SAFE's contractual provisions (including its integration clause and the absence of express product-readiness representations and warranties) and Delaware common law (particularly on the scienter element of common-law fraud and the heightened clear-and-convincing evidentiary standard). However, the litigation risk remains meaningful for several reasons. First, the factual record on the scienter question — specifically, what Lumos's management knew or should have known about Prism Core v2.0's development trajectory in August 2023 — is ambiguous and has not been fully developed. Internal communications, development logs, and testing data could cut either way in discovery. Second, the negligent misrepresentation theory, which does not require scienter, presents a moderately higher level of exposure for the Company. Third, the practical and reputational harm of protracted litigation with a prominent venture capital fund would be disproportionate to the amount in controversy, particularly given Lumos's limited cash position, short operating runway, and small team.

Accordingly, the recommended course of action is to pursue a negotiated resolution in the form of a mutual termination of the SAFE with a full refund of the $3,500,000 purchase amount, accompanied by mutual general releases and mutual non-disparagement obligations. This approach eliminates litigation exposure, preserves the Company's reputation and relationships within the venture community, and allows management to focus its limited resources on remediating the underlying product issues.

This memorandum proceeds as follows: Part II sets forth the relevant factual background. Part III provides the legal analysis, addressing common-law fraud, negligent misrepresentation, contractual defenses, rescission, and statute of limitations considerations, as well as practical litigation risk factors. Part IV presents a summary assessment table. Part V states our conclusions and recommendations.

II. FACTUAL BACKGROUND

A. The Parties

Lumos Analytics Inc. Lumos is a Delaware C-corporation headquartered at 340 Folsom Street, Suite 1100, San Francisco, California 94105. The Company is a seed-stage enterprise software company operating in the SaaS/fintech vertical. Lumos's principal product is an AI-driven financial analytics platform marketed under the trade name "Lumos Prism," which is designed to provide automated compliance scoring and risk analytics for financial institutions. As of July 2023, the Company reported monthly recurring revenue ("MRR") of approximately $38,000, derived primarily from a small number of early-adopter enterprise customers and pilot programs. As of August 2023, the Company employed fourteen (14) full-time employees across engineering, product, sales, and administrative functions.

The Company's officers are as follows:

• Priya Narasimhan — Co-Founder, Chief Executive Officer & President

• Elliot Marsh — Co-Founder, Chief Technology Officer

• Danielle Okoye — Chief Financial Officer (joined the Company in March 2023)

The Company's Board of Directors consists of three members:

• Priya Narasimhan — Chair of the Board

• Elliot Marsh — Director

• Kenji Watanabe — Independent Director (appointed July 2023)

Vantage Peak Ventures Fund II, L.P. Vantage Peak is a Delaware limited partnership organized as a venture capital fund. Its general partner is Vantage Peak Capital Management LLC. Fund II is a 2022-vintage fund with total committed capital of approximately $185 million, focused on seed and early-stage investments in enterprise technology and financial services. The fund's managing partners are Catherine Aldridge and Raymond Petrov. The deal lead for the Lumos investment was Samantha Reyes, a Principal at the firm, who managed the diligence process and negotiated the SAFE terms on behalf of VPV.

Vantage Peak is represented in this matter by Whitfield Harte & Associates LLP, a Palo Alto-based law firm. The lead attorney is Jonathan Whitfield (Partner), with Megan Trost (Associate) serving as the primary day-to-day contact. Whitfield Harte is the firm that transmitted the October 18, 2023 demand letter on behalf of VPV.

B. The SAFE Financing Round

In the summer of 2023, Lumos initiated a fundraising round with a target of $6,800,000 in total investment, to be raised through Post-Money SAFEs based on the standard Calderon Partners LLC SAFE form, with certain modifications negotiated with investors. The key commercial terms of the SAFEs were as follows:

• Post-money valuation cap: $28,000,000

• discount: None

• Form: Post-Money SAFE (YC standard form, modified)

Vantage Peak committed to investing $3,500,000 as the lead investor in the round. The Vantage Peak SAFE was executed on September 12, 2023. Funds in the amount of $3,500,000 were wired by Vantage Peak to Lumos's primary operating account at Silicon Valley Commerce Bank, Account Number 8801-4427-3390, on or about the date of execution.

Following the close of the Vantage Peak SAFE, three additional investors participated or expressed interest in the round:

1. Ridgeline Angel Fund, L.P. — Committed $1,200,000 via a Post-Money SAFE executed and funded on September 22, 2023.

2. Canopy Growth Capital LLC — Committed $1,100,000 via a Post-Money SAFE executed and funded on September 29, 2023.

3. Atlas Fintech Syndicate, L.P. — Signed a term sheet on October 4, 2023 for $1,000,000, but the corresponding SAFE was never executed, and Atlas ultimately withdrew its interest following the events described below.

In total, $5,800,000 was funded into the round prior to the events giving rise to this dispute. The round did not reach its target of $6,800,000.

C. The Pitch Materials and Product Representations

In August 2023, Lumos prepared and circulated an investor pitch deck and related materials to Vantage Peak in connection with the fundraising round. These materials were subsequently provided, in substantially the same form, to the other investors participating in the round. The pitch deck included a product roadmap and technology overview section in which Lumos represented that its machine-learning compliance scoring module, denominated Prism Core v2.0, was "beta-ready by Q4 2023."

Prism Core v2.0 is the core differentiating technology underlying the Lumos Prism platform. It is a machine-learning model designed to score the compliance risk of financial transactions against a proprietary benchmark. The module is covered by U.S. Provisional Patent Application No. 63/987,214, filed on June 15, 2023, and represents the principal source of Lumos's claimed competitive advantage in its target market segment.

The "beta-ready by Q4 2023" representation was a central element of Lumos's investment thesis as presented to prospective investors. Vantage Peak's investment decision, as communicated by Samantha Reyes during the diligence process, was predicated in significant part on the expectation that Prism Core v2.0 would reach a functional beta release in the fourth quarter of 2023, enabling customer pilots and revenue acceleration in the first half of 2024.

These representations were made prior to the execution of the Vantage Peak SAFE on September 12, 2023, and were part of the inducement for Vantage Peak's investment decision. The same materials were also provided to Ridgeline, Canopy Growth, and Atlas prior to their respective commitments.

D. The Product Failure and Disclosure

On October 8, 2023, Peralta IP Consulting LLC, an independent technical consulting firm retained by Lumos to evaluate the performance of Prism Core v2.0, completed its functionality and accuracy validation testing of the module. The principal consultant responsible for the engagement was Dr. Amir Farouk, a specialist in machine-learning model validation.

On October 9, 2023, Peralta issued its formal validation report. The report concluded that Prism Core v2.0 achieved only 61% accuracy against the relevant compliance-scoring benchmark. The target accuracy threshold for the module to be considered beta-ready was 92%. The 31-percentage-point gap between actual and target performance represented a fundamental shortfall in the module's core functionality and indicated that the product was materially further from beta readiness than had been anticipated.

On October 10, 2023, CTO Elliot Marsh disclosed the Peralta validation results to the Lumos Board of Directors. During this disclosure, Marsh estimated that 4 to 6 months of additional development would be required to remediate the module's accuracy deficiencies and bring it to a state of beta readiness. This timeline implied that the earliest achievable beta launch would be in the range of February to April 2024, well beyond the "Q4 2023" timeframe represented in the August 2023 pitch materials.

On October 12, 2023, the Lumos Board of Directors convened a formal board meeting to discuss the Peralta report and its implications. The board determined that the Prism Core v2.0 failure constituted a material product setback with significant implications for the Company's business plan, revenue projections, and investor relations. The board debated the Company's disclosure obligations, including whether the information rights provisions of the executed SAFEs required prompt notification to investors, and ultimately authorized CEO Narasimhan to inform the lead investor.

On October 13, 2023, CEO Priya Narasimhan notified Vantage Peak's Samantha Reyes of the Peralta validation results and the estimated remediation timeline. This notification was the first communication to any investor regarding the product setback.

Key timeline gap. The pitch materials representing Prism Core v2.0 as "beta-ready by Q4 2023" were circulated in August 2023. At that time, the formal validation testing by Peralta had not yet been conducted — the testing was completed on October 8, 2023, approximately two months later. Whether Lumos's management had reason to know in August 2023 that the "beta-ready by Q4 2023" representation was unreliable, unsupported, or at risk of being inaccurate is a contested factual question that lies at the heart of the scienter inquiry discussed in Part III below.

E. Vantage Peak's Withdrawal and Demand

On October 15, 2023 — two days after receiving notification of the product setback — Vantage Peak communicated to Lumos a request for the return of its invested funds, citing alleged material misrepresentation regarding product readiness as the basis for the request.

On October 18, 2023, Vantage Peak formalized its withdrawal from the SAFE. On the same date, Lumos received a demand letter from Whitfield Harte & Associates LLP, acting as counsel for Vantage Peak. The demand letter asserted claims of fraud and material misrepresentation under Delaware law, and demanded a full refund of the $3,500,000 SAFE purchase amount. The demand letter specifically referenced the August 2023 pitch materials, the "beta-ready by Q4 2023" representation, and the Peralta validation report as the basis for Vantage Peak's claims.

Following Vantage Peak's withdrawal, the remaining funded investors — Ridgeline Angel Fund and Canopy Growth Capital — also initiated communications regarding their own rights and potential withdrawal. Atlas Fintech Syndicate, whose SAFE was never executed, withdrew its expression of interest entirely. The cascade effect of these developments is discussed further in Part III.F below.

III. LEGAL ANALYSIS

A. Common-Law Fraud Under Delaware Law

1. Elements of the Claim. Under Delaware law, a plaintiff asserting a claim for common-law fraud must establish each of the following five elements:

(a) A false representation, usually of fact, made by the defendant to the plaintiff;

(b) The defendant's knowledge or belief that the representation was false, or that the representation was made with reckless indifference to its truth or falsity (scienter);

(d) The plaintiff's action or inaction was taken in justifiable reliance on the representation; and

(e) The plaintiff suffered damage as a proximate result of such reliance.

See Stephenson v. Capano Dev., Inc., 462 A.2d 1069, 1074 (Del. 1983); Gaffin v. Teledyne, Inc., 611 A.2d 467, 472 (Del. 1992); Trenwick Am. Litig. Trust v. Rowan Whitfield CPAs LLP, L.L.P., 906 A.2d 168, 207 (Del. Ch. 2006), aff'd, 931 A.2d 438 (Del. 2007).

Critically, Delaware law imposes a heightened standard of proof for fraud claims. Unlike most civil claims, which are decided on a preponderance-of-the-evidence standard, a fraud plaintiff must prove each element by clear and convincing evidence. See Stephenson, 462 A.2d at 1074; Metro Commc'n Corp. BVI v. Advanced Mobilecomm Techs. Inc., 854 A.2d 121, 131 (Del. Ch. 2004). This heightened evidentiary burden is a significant factor in assessing Lumos's litigation exposure, as discussed below.

2. Application to Lumos's Representations. Each element of the fraud analysis is addressed in turn.

a. False Representation

The threshold question is whether the "beta-ready by Q4 2023" statement in the August 2023 pitch materials constitutes a "false representation of fact" within the meaning of Delaware fraud law. Vantage Peak will argue that this was an objectively false representation regarding the readiness of Prism Core v2.0, as conclusively demonstrated by the Peralta validation report's finding of only 61% accuracy against a 92% target. On its face, the magnitude of the shortfall — a 31-percentage-point gap — suggests that the product was not merely behind schedule but was fundamentally not in a condition to achieve beta readiness within the represented timeframe.

Lumos has a counter-argument on this element. At the time the representation was made — August 2023 — the formal validation testing by Peralta had not yet been conducted. That testing was not completed until October 8, 2023, nearly two months after the pitch materials were circulated. Accordingly, Lumos can argue that the "beta-ready by Q4 2023" statement was a good-faith, forward-looking projection based on the information available to management at the time, not a statement of present fact. Under Delaware law, expressions of opinion, statements of belief, and forward-looking projections are generally not actionable as fraud unless the speaker did not genuinely hold the stated opinion or belief at the time the statement was made. See In re IBP, Inc. S'holders Litig., 789 A.2d 14, 68–69 (Del. Ch. 2001).

However, this distinction is not dispositive. Delaware courts have recognized that a statement characterized as a "projection" or "estimate" may nonetheless be actionable if it implies a present factual basis — for example, if it implies that the speaker has conducted sufficient analysis to support the projection and no information available to the speaker is materially inconsistent with it. See Ams. Mining Corp. v. Theriault, 51 A.3d 1213, 1239 (Del. 2012). The "beta-ready by Q4 2023" representation, while nominally forward-looking, implicitly represents that the product's development trajectory as of August 2023 supported the stated timeline. If the facts available to management at that time did not support such a trajectory, the representation could be deemed a misstatement of present fact (i.e., a misstatement about the product's current development status and the reasonableness of the projected timeline).

In sum, the false-representation element is contested but arguable for both sides. The resolution will depend heavily on the factual record regarding what information was available to Lumos's management in August 2023.

b. Scienter

Scienter is the most critical and debatable element of the fraud claim. To satisfy scienter, Vantage Peak must prove by clear and convincing evidence that Lumos's management — specifically, CEO Priya Narasimhan and CTO Elliot Marsh, who were primarily responsible for the pitch materials and the product roadmap — either (i) knew the "beta-ready by Q4 2023" representation was false when it was made, or (ii) made the representation with reckless indifference to its truth or falsity.

The central factual question is: What did CTO Marsh and CEO Narasimhan know or have reason to know in August 2023 about Prism Core v2.0's development trajectory? Specifically:

(i) What internal development milestones and testing data were available to Marsh and Narasimhan before August 2023? Were there interim accuracy benchmarks, prototype test runs, or internal validation metrics that indicated the module's performance trajectory?

(ii) Were there any internal communications — emails, Meridian Solutions messages, engineering reports, sprint retrospectives, or board memoranda — that indicated the 92% accuracy target was at risk or that the Q4 2023 beta timeline was not achievable?

(iii) What was the factual basis for the "beta-ready by Q4 2023" projection? Was it derived from a documented engineering roadmap with identified milestones, or was it an aspirational target without a concrete technical foundation?

If the evidence shows that Lumos's management genuinely believed in August 2023 that the Q4 2023 beta timeline was achievable — based on the development data then available — then scienter is lacking. A good-faith belief that later proves incorrect is not fraud, even if the belief turns out to have been overly optimistic. See Prairie Capital III, L.P. v. Double E Holding Corp., 132 A.3d 35, 50–51 (Del. Ch. 2015) (noting that fraud requires more than a statement that turns out to be inaccurate; the plaintiff must show that the defendant knew or recklessly disregarded the falsity at the time of the statement).

Conversely, if internal evidence shows early warning signs that were ignored or suppressed — for example, if internal test results from July or early August 2023 showed accuracy rates well below the 92% target, or if engineering team members raised concerns about the feasibility of the Q4 timeline that were overridden by management — then the scienter analysis becomes significantly more adverse for Lumos. In that scenario, Vantage Peak could argue that management knew the representation was false or, at minimum, made it with reckless indifference to the risk that the product would not achieve the stated milestone.

We have not yet had the opportunity to conduct a thorough review of Lumos's internal communications and development records from the relevant period. This review is critical and should be prioritized. I recommend that we immediately issue a litigation hold notice to Lumos and request the preservation and production of all internal communications, development logs, testing data, engineering reports, and board materials from June through September 2023 related to Prism Core v2.0's development status and the "beta-ready" timeline. This evidence will be determinative of the scienter question and, by extension, of the overall strength of the fraud claim.

c. Intent to Induce

This element is likely satisfied and will be difficult for Lumos to contest. The August 2023 pitch materials were expressly created and circulated for the purpose of soliciting investment in Lumos. The "beta-ready by Q4 2023" representation was included in the product roadmap section of the pitch deck, which is a standard component of investor solicitation materials designed to communicate the company's value proposition and development trajectory. There is no credible argument that the pitch materials were prepared for any purpose other than inducing prospective investors to commit capital. Accordingly, this element does not present a meaningful line of defense.

d. Justifiable Reliance

The justifiable reliance element requires analysis of whether Vantage Peak's reliance on the "beta-ready by Q4 2023" representation was reasonable under the circumstances. This analysis is informed by the sophistication of the parties and the nature of the representation.

Vantage Peak is a sophisticated institutional investor. It operates a $185 million venture capital fund, employs experienced investment professionals (including a dedicated deal lead, Samantha Reyes, who is a Principal at the firm), and is represented by established counsel (Whitfield Harte & Associates LLP). Delaware courts apply a reasonableness standard to the reliance element and generally hold that sophisticated parties with access to information and the resources to conduct independent diligence bear a greater burden in establishing justifiable reliance. See Siga Techs., Inc. v. PharmAthene, Inc., 67 A.3d 330, 348 (Del. 2013); Great Lakes Chem. Corp. v. Pharmacia Corp., 788 A.2d 544, 555 (Del. Ch. 2001).

Lumos can argue that Vantage Peak, as a sophisticated venture capital fund with extensive experience in seed-stage technology investments, was in a position to — and should have — independently validated Prism Core v2.0's technical readiness prior to executing the SAFE. The fact that Vantage Peak did not commission its own independent technical assessment of the module's development status weighs against a finding of justifiable reliance. Sophisticated investors are expected to "protect themselves" and cannot blindly rely on a startup's pitch deck without conducting their own diligence. See RAA Mgmt., LLC v. Savage Sports Holdings, Inc., 45 A.3d 107, 118–19 (Del. 2012).

However, this argument has limits. Delaware law recognizes that even sophisticated parties may justifiably rely on specific factual representations made by the counterparty, particularly where those representations relate to matters within the counterparty's superior knowledge or control. See Airborne Health, Inc. v. Squid Soap, LP, 984 A.2d 126, 143–44 (Del. Ch. 2009). The development status of Prism Core v2.0 was a matter squarely within Lumos's knowledge and control; Vantage Peak had no independent access to the module's source code, internal testing data, or engineering roadmap. The "beta-ready by Q4 2023" representation was a specific, time-bound statement about a concrete product milestone, not a vague expression of optimism. A court could reasonably conclude that reliance on such a representation was justified, even by a sophisticated investor, given the informational asymmetry inherent in early-stage venture investments.

Additionally, the fact that Vantage Peak did not independently validate the product's technical readiness is not unusual in the context of seed-stage SAFE investments, where the speed and informality of the fundraising process often preclude the kind of exhaustive technical diligence that might be expected in a later-stage preferred stock round with full representations and warranties.

On balance, the reliance element is contested but not clearly in Lumos's favor. The sophisticated-investor defense is supportive but likely not dispositive, particularly given the specificity of the representation and the informational asymmetry.

e. Damages

If Vantage Peak succeeds on a fraud claim, the measure of damages would be the return of the $3,500,000 SAFE purchase amount — i.e., the amount of the investment that was induced by the alleged misrepresentation. Vantage Peak might also seek consequential damages, which could include the opportunity cost of deploying the $3,500,000 elsewhere during the investment period, as well as due diligence expenses, legal fees, and related costs incurred in connection with the Lumos investment and the subsequent dispute.

More likely, however, Vantage Peak would seek rescission of the SAFE as the primary remedy, which would restore both parties to the pre-investment status quo. The rescission remedy is discussed separately in Part III.D below.

3. Assessment of Lumos's Exposure on Common-Law Fraud. In summary, the scienter element is the primary battleground on the common-law fraud claim. Lumos has a reasonable argument that the August 2023 representations were good-faith, forward-looking statements based on the information available to management at the time, and that the subsequent product failure was an unforeseen development that does not give rise to an inference of fraud.

However, several factors complicate this defense:

• The gap between actual performance (61%) and the target threshold (92%) is substantial — a 31-percentage-point shortfall. This magnitude raises a natural inference that the product was far from beta-ready even at the time the representation was made, which could undermine the claim that management's belief in the Q4 timeline was reasonable.

• The factual record on what management knew in August 2023 is undeveloped. Until we review the internal communications and development data, we cannot assess with confidence whether the good-faith defense will hold.

• While the heightened clear-and-convincing standard of proof benefits Lumos, it is not an impenetrable shield — particularly if the internal evidence is adverse.

Overall risk assessment on common-law fraud: MODERATE. The claim is viable but faces significant hurdles on scienter and the standard of proof. The outcome is highly fact-dependent and will be determined largely by what the internal record reveals.

B. Negligent Misrepresentation Under Delaware Law

1. Elements of the Claim. Delaware law recognizes a cause of action for negligent misrepresentation. The elements are as follows:

(a) The defendant owed a pecuniary duty to provide accurate information to the plaintiff (or the defendant had a pecuniary interest in the transaction);

(b) The defendant supplied false information to the plaintiff;

(d) The plaintiff justifiably relied on the information and suffered pecuniary loss as a result.

See Outdoor Techs., Inc. v. Allfirst Fin., Inc., 2001 WL 541472, at 5 (Del. Super. Ct. Apr. 24, 2001); Guardian Constr. Co. v. Tetra Tech Richardson, Inc.*, 583 A.2d 1378, 1386 (Del. Super. Ct. 1990).

The critical distinction between negligent misrepresentation and common-law fraud is the absence of a scienter requirement. A negligent misrepresentation claim does not require proof that the defendant knew the information was false or acted with reckless indifference to the truth. Instead, the plaintiff need only show that the defendant failed to exercise reasonable care in obtaining or communicating the information. The standard of proof is also lower: negligent misrepresentation requires proof by a preponderance of the evidence, not the heightened clear-and-convincing standard applicable to fraud.

2. Application to Lumos's Representations. Pecuniary duty. Lumos owed a duty of reasonable care in providing information to prospective investors in connection with the fundraising round. The circulation of investor pitch materials is a classic context in which this duty arises. The August 2023 pitch deck was prepared for the specific purpose of soliciting investment capital, and Lumos had a direct pecuniary interest in the accuracy of the information conveyed to investors. This element is straightforwardly satisfied.

False information. For the same reasons discussed in Part III.A.2.a above, Vantage Peak will argue that the "beta-ready by Q4 2023" representation was false. The analysis of this element is the same as for the fraud claim.

Failure to exercise reasonable care. This is the key element for the negligent misrepresentation theory, and it is where Vantage Peak's case is meaningfully stronger than its fraud case. The question is not whether Lumos knew the representation was false (scienter), but whether Lumos exercised reasonable care in formulating and communicating the "beta-ready by Q4 2023" projection.

Vantage Peak will likely argue that Lumos failed to exercise reasonable care by representing a specific product readiness timeline to investors without first conducting adequate internal validation or testing to confirm that the timeline was achievable. The fact that formal validation testing (by Peralta) was not completed until October 8, 2023 — nearly two months after the pitch materials were circulated — suggests that the "beta-ready by Q4 2023" representation may have been made without a sufficiently rigorous empirical foundation. If Lumos's management projected beta readiness by Q4 2023 without having validated the module's accuracy against the target benchmark, a court could find that the Company failed to exercise the level of care that a reasonable person in similar circumstances would have exercised in communicating such a representation to investors.

Lumos's defense on this element would be that the projection was based on the engineering team's assessment of the product's development trajectory, informed by internal milestones and engineering judgment, and that it was not unreasonable to rely on this assessment without first completing formal third-party validation. The strength of this defense depends, again, on the internal factual record — specifically, whether there was a reasonable basis for the engineering team's assessment in August 2023 and whether any internal data suggested the 92% target was at risk.

Justifiable reliance. The reliance analysis for negligent misrepresentation is substantially the same as for fraud. However, Delaware courts may be somewhat more lenient in finding reliance reasonable in the negligent misrepresentation context, particularly where the representation relates to matters within the defendant's superior knowledge. The sophisticated-investor defense remains relevant but may carry less weight.

Risk assessment on negligent misrepresentation: MODERATE TO HIGH. The absence of a scienter requirement and the lower preponderance-of-the-evidence standard make this theory a more accessible avenue for Vantage Peak. Lumos's exposure is meaningfully higher on negligent misrepresentation than on common-law fraud. The outcome hinges on whether Lumos can demonstrate that it had a reasonable basis for the "beta-ready" statement and exercised due care in formulating the projection.

C. Contractual Defenses: The SAFE's Limitation-of-Liability and Integration Clauses

1. Integration Clause. The executed SAFE between Lumos and Vantage Peak contains a standard integration (or merger) clause providing that the SAFE constitutes the entire agreement between the parties with respect to the subject matter thereof and supersedes all prior negotiations, representations, warranties, and agreements, whether written or oral.

Argument for Lumos. Lumos can argue that the integration clause bars Vantage Peak from relying on the pre-contractual August 2023 pitch representations as the basis for a misrepresentation claim. Under this theory, by executing the SAFE with an integration clause, Vantage Peak acknowledged that its rights and obligations vis-à-vis Lumos are governed exclusively by the terms of the SAFE itself, and that any representations or promises made outside the four corners of the SAFE are merged into the agreement and have no independent legal effect. The investor's remedies are limited to those set forth in the SAFE, which does not provide a right to a refund based on pre-contractual representations.

Counter-argument. Under well-established Delaware law, an integration clause does not bar claims for fraudulent inducement. A party cannot contractually insulate itself from liability for fraud in the inducement, because a contract procured by fraud is voidable at the election of the defrauded party. See Abry Partners V, L.P. v. F & W Acquisition LLC, 891 A.2d 1032, 1059 (Del. Ch. 2006) ("[A] party cannot contractually immunize itself from liability for making affirmative misrepresentations of fact that constitute fraud."); RAA Mgmt., LLC, 45 A.3d at 119.

However, the integration clause may have greater force with respect to a negligent misrepresentation claim. If the SAFE contains not merely a generic integration clause but also a specific non-reliance or disclaimer-of-representations clause — sometimes referred to as a "big-boy" provision — in which Vantage Peak expressly represents that it has not relied on any representations or statements by Lumos other than those set forth in the SAFE, this could significantly limit Vantage Peak's ability to assert a negligent misrepresentation claim based on extra-contractual statements. See Abry Partners, 891 A.2d at 1058 (holding that a contractual representation that the buyer "did not rely on any representation, statement, or agreement other than those expressly set forth in this Agreement" can bar claims for negligent or innocent misrepresentation, though not for intentional fraud); IOTEX Commc'ns, Inc. v. Defries, 1998 WL 914265, at *3 (Del. Ch. Dec. 21, 1998).

Analysis of the Vantage Peak SAFE. We need to carefully review the specific language of the integration clause in the executed SAFE, as well as any accompanying disclaimer or non-reliance provisions. The standard YC Post-Money SAFE form includes a relatively brief integration clause but does not typically include a robust "big-boy" or express non-reliance representation. If the modifications negotiated with Vantage Peak included the addition of such a clause, Lumos's position on the negligent misrepresentation claim would be materially strengthened. If no such clause was added — which is the more likely scenario given the typical dynamics of a seed-stage SAFE negotiation — the integration clause alone will provide limited protection.

I recommend that we obtain and review the fully executed SAFE, with all modifications, to determine the precise scope of the integration clause and whether any non-reliance language was included.

2. Limitation-of-Liability Provisions. We should also analyze whether the SAFE contains any limitation-of-liability provisions or caps on damages that could limit Lumos's exposure in the event of a successful claim.

The standard YC Post-Money SAFE form does not include extensive limitation-of-liability provisions. The SAFE is a relatively streamlined instrument that defines the investor's rights primarily in terms of conversion mechanics upon the occurrence of specified triggering events (equity financing, liquidity event, dissolution). However, the modified form used in this transaction should be reviewed for any negotiated additions. It is possible that during the negotiation process, one or both parties sought to include provisions addressing liability, indemnification, or exclusive remedies.

If the SAFE limits the investor's remedies to the return of the purchase amount upon a Dissolution Event — which is a standard feature of the YC SAFE form — Lumos may argue that this exclusive remedy structure preempts extra-contractual damage claims. Under this theory, the SAFE establishes a comprehensive framework for the investor's recovery rights, and claims seeking relief beyond that framework (such as consequential damages, opportunity costs, or punitive damages) are not available.

Counter-argument. Limitation-of-liability clauses are generally not enforceable against claims of intentional fraud under Delaware law. A party cannot contractually limit its liability for its own deliberate wrongdoing. See SIGA Techs., 67 A.3d at 348. Accordingly, even if the SAFE contains a limitation-of-liability provision, it would not protect Lumos against a successful fraud claim.

With respect to negligent misrepresentation, the enforceability of a limitation-of-liability clause is more nuanced and would depend on the specific language of the provision. A broadly drafted limitation that encompasses "all claims arising out of or relating to this Agreement" might extend to negligent misrepresentation claims, while a narrower provision limited to breaches of the SAFE's own terms might not.

Assessment: The limitation-of-liability defense is of limited utility given the standard form of the YC SAFE and the inapplicability of such provisions to intentional fraud claims.

3. Absence of Express Representations and Warranties in the SAFE. Unlike a preferred stock purchase agreement or a traditional securities purchase agreement, the standard Post-Money SAFE does not contain extensive representations and warranties by the issuer regarding the company's business, financial condition, intellectual property, product development, or technology. The YC SAFE form is intentionally minimalist in this regard, reflecting the instrument's design as a lightweight, founder-friendly financing mechanism for early-stage companies.

This absence of contractual representations cuts both ways:

(a) Argument for Lumos. Lumos can argue that Vantage Peak, as a sophisticated investor represented by experienced counsel, accepted the SAFE with full awareness that the instrument contained no product-readiness warranty or representation. By choosing to invest via a SAFE — as opposed to a preferred stock round with full representations and warranties, indemnification obligations, and closing conditions — Vantage Peak assumed the inherent risks associated with a less-protective investment structure. The absence of a contractual product-readiness warranty indicates that Vantage Peak was willing to bear the risk that the product might not achieve the milestones discussed in the pitch materials, or at minimum, that it did not deem such a warranty important enough to negotiate for.

(b) Argument for Vantage Peak. Conversely, Vantage Peak can argue that the absence of contractual representations and warranties in the SAFE means that it was entitled to rely on the extra-contractual representations made in the pitch materials, precisely because there were no contractual representations to supersede or displace them. In other words, the SAFE does not contain an express warranty regarding product readiness, but neither does it contain a disclaimer or non-reliance clause negating the pitch representations. In the absence of such contractual provisions, the pre-contractual representations retain their independent legal significance, and Vantage Peak was justified in relying on them.

This issue is closely related to the integration clause analysis discussed above. The resolution depends on the overall structure of the SAFE, the presence or absence of non-reliance language, and the court's assessment of the reasonable expectations of the parties in the context of a seed-stage SAFE financing.

D. Potential Rescission Claim

In addition to (or in lieu of) a claim for money damages, Vantage Peak may seek rescission of the SAFE on equitable grounds. Rescission is the unwinding of a contract and the restoration of the parties to the positions they occupied prior to entering into the agreement.

Under Delaware law, a court may grant rescission where a contract was induced by material misrepresentation (whether fraudulent or negligent), or where there is a mutual mistake regarding a basic assumption underlying the contract. See Restatement (Second) of Contracts §§ 152, 164 (1981); see also Hollowell Private Capital Int'l, Ltd. v. Apollo Mgmt., L.P., 794 A.2d 1141, 1151 (Del. 2002); BAE Sys. Info. & Elec. Sys. Integration, Inc. v. Harborline Industries, 2009 WL 264088, at *6 (Del. Ch. Feb. 3, 2009).

If rescission is granted, the remedy would be the return of the $3,500,000 purchase amount to Vantage Peak, and the cancellation of the SAFE and all rights thereunder. This is the same economic outcome that would result from a negotiated mutual termination and refund.

Rescission is an equitable remedy and is within the court's discretion. In exercising this discretion, Delaware courts weigh the equities of the situation, including the promptness of the plaintiff's claim (whether the plaintiff acted with reasonable diligence upon discovering the alleged misrepresentation), the ability to restore the parties to the status quo ante, whether monetary damages are an adequate alternative remedy, and whether the plaintiff has unclean hands or is otherwise estopped from seeking equitable relief. See Cantera v. Harborline Corporation Senior Living Servs., Inc., 1999 WL 118823, at *5 (Del. Ch. Feb. 18, 1999).

Here, Vantage Peak acted promptly upon learning of the product setback — requesting a return of funds on October 15, 2023, just two days after receiving notice on October 13, 2023. The status quo ante is readily restorable: the transaction was a simple cash-for-SAFE exchange, and the funds can be returned without significant unwinding complications. These factors favor rescission.

Risk assessment: MODERATE. The economic outcome of rescission is identical to the recommended negotiated resolution (full refund). Accordingly, the risk of a rescission award does not independently increase Lumos's total financial exposure; rather, it reinforces the pragmatic case for a negotiated refund on consensual terms.

E. Statute of Limitations Considerations

Under Delaware law, the statute of limitations for fraud claims is three years from the date of the wrongful act or, under the discovery rule, from the date the plaintiff knew or should have known of the facts giving rise to the claim. 10 Del. C. § 8106.

Vantage Peak learned of the Prism Core v2.0 product failure on October 13, 2023, when CEO Narasimhan provided notification. Vantage Peak transmitted its demand letter on October 18, 2023, and any litigation would presumably be filed in the near term. Any claim filed within this timeframe would be well within the three-year limitations period, and the statute of limitations is not a practical defense at this stage of the dispute.

We note this issue for completeness and to confirm that any delay in resolving the dispute does not implicate limitations concerns for Lumos's own potential counterclaims or cross-claims, should such claims become relevant.

F. Litigation Risk and Practical Considerations

Beyond the doctrinal legal analysis, several practical factors bear significantly on the risk assessment and the recommended course of action.

1. Factual Uncertainty on Scienter. As discussed at length in Part III.A.2.b, the strength of Lumos's defense to the common-law fraud claim depends critically on the internal factual record regarding what CTO Marsh and CEO Narasimhan knew about Prism Core v2.0's development status in August 2023. This factual record has not yet been fully developed or reviewed by outside counsel.

This factual uncertainty creates a dual-edged litigation risk:

• If discovery reveals that the internal record supports a good-faith defense — i.e., that management had a reasonable basis for the "beta-ready by Q4 2023" projection and was not aware of any data suggesting the 92% accuracy target was at risk — then Lumos's litigation position is strong, and Vantage Peak would face significant difficulty establishing scienter by clear and convincing evidence.

• If, however, discovery reveals adverse internal communications — for example, emails or Meridian Solutions messages in which engineering team members expressed skepticism about the Q4 timeline, internal test results showing accuracy rates substantially below 92%, or evidence that management was aware of risk factors that were not disclosed to investors — then Lumos's position would be materially weakened, and the scienter element could be established.

Litigation would necessarily involve extensive document discovery of Lumos's internal communications, development logs, project management records (e.g., JIRA or equivalent tools), testing data, board materials, and executive communications from the June through September 2023 period. This discovery process would be invasive, time-consuming, and distracting for a 14-person startup, and it carries the inherent risk that the internal record may contain unfavorable evidence that management has not yet surfaced to outside counsel.

2. Reputational Impact. Vantage Peak Ventures is a prominent early-stage venture fund with a $185 million fund, a well-known brand in the technology venture community, and extensive relationships with other investors, portfolio companies, and industry participants. Litigation with a well-known VC firm — particularly on fraud allegations — would almost certainly become known within the venture ecosystem and would likely damage Lumos's ability to raise future capital. Prospective investors in any future fundraising round would conduct background diligence and would inevitably discover the pending or resolved fraud litigation. The reputational stain of fraud allegations, even if ultimately unfounded, could effectively disqualify Lumos from raising institutional venture capital for an extended period.

Even if Lumos ultimately prevails in litigation, the cost of defense — both in financial terms and in terms of management time and attention — would be existentially threatening to a seed-stage company. As of the current date, assuming a full refund of all investor funds ($5,800,000), Lumos's cash position would be reduced to approximately $390,000, reflecting roughly $30,000 in net operating expenses and legal fees incurred during the round period. At the Company's current monthly burn rate of approximately $95,000, this cash position provides only approximately 4.1 months of operating runway. Litigation defense costs — including outside counsel fees, expert witnesses, e-discovery vendors, and related expenses — could easily consume the Company's entire cash reserve within the first few months of active litigation, forcing the Company to seek emergency financing or cease operations.

3. Cascade Effect on Co-Investors. Vantage Peak's withdrawal has already triggered a cascade effect among the other investors in the round:

• Ridgeline Angel Fund, L.P. ($1,200,000 funded) has communicated its intent to seek a return of funds.

• Canopy Growth Capital LLC ($1,100,000 funded) has similarly indicated that it is evaluating its rights and may seek withdrawal.

• Atlas Fintech Syndicate, L.P. ($1,000,000 term sheet signed, SAFE never executed) has withdrawn its interest entirely and will not be proceeding with the investment.

Protracted litigation with Vantage Peak would further erode investor and market confidence, potentially making it impossible for Lumos to retain the Ridgeline and Canopy Growth investments even if those investors might otherwise have been willing to remain in the round. The cascade effect also creates the risk of additional claims by Ridgeline and Canopy Growth, who received substantially the same pitch materials and could assert similar fraud and misrepresentation theories.

4. Cost-Benefit Analysis: Litigation vs. Negotiated Resolution. The foregoing considerations strongly favor a negotiated resolution over contested litigation. The cost-benefit analysis may be summarized as follows:

• A full refund of $3,500,000 to Vantage Peak (or $5,800,000 across all funded investors) restores the parties to the pre-round status quo. This is the same economic outcome that would result from a successful rescission claim by Vantage Peak.

• Lumos's pre-round cash position was approximately $420,000. After accounting for approximately $30,000 in net operating expenses and legal fees during the round period, the post-refund cash position would be approximately $390,000.

• Litigation defense costs — including outside counsel fees, e-discovery, expert retention, and related expenses — would quickly exceed the Company's available cash resources. A contested fraud litigation through summary judgment alone could cost $500,000 to $1,000,000 or more, far exceeding the Company's entire cash reserve.

• A mutual termination with full refund and mutual general releases eliminates ongoing legal exposure, avoids the risk of an adverse judgment (which could include consequential damages in addition to the refund amount), and preserves the option to pursue future fundraising once the Prism Core v2.0 product issues are remediated.

In short, the economic outcome of the most likely litigation result (rescission and refund) is identical to the proposed negotiated outcome, but litigation adds substantial cost, delay, risk, and reputational damage. The negotiated resolution is clearly the superior course of action from a risk-management perspective.

IV. ASSESSMENT OF LUMOS'S DEFENSES — SUMMARY TABLE

The following table summarizes the assessment of each potential defense and the corresponding level of litigation risk:

V. CONCLUSION AND RECOMMENDATION

Based on the foregoing analysis, I conclude and recommend as follows:

1. Lumos has colorable but not airtight defenses to Vantage Peak's potential fraud and misrepresentation claims. The Company is not without arguments — the scienter element of the fraud claim is genuinely contested, the heightened standard of proof provides meaningful protection, and the sophisticated-investor defense and the SAFE's integration clause offer additional (if limited) support. However, none of these defenses is sufficiently strong to warrant confidence that Lumos would prevail in contested litigation.

2. The scienter element is fact-intensive and uncertain. The resolution of the fraud claim turns on what Lumos's management knew about Prism Core v2.0's development trajectory in August 2023. Until the internal factual record is fully reviewed, we cannot assess with confidence whether the good-faith defense will withstand scrutiny. Discovery could produce evidence that either supports or undermines Lumos's position, and the risk of adverse findings is real.

3. The negligent misrepresentation claim presents higher exposure than the fraud claim because it does not require scienter — only a failure to exercise reasonable care. Given the apparent absence of formal validation testing prior to the circulation of the pitch materials, Vantage Peak has a credible argument that Lumos failed to exercise due care in representing a specific product readiness timeline to investors. This claim is subject to the lower preponderance-of-the-evidence standard and does not face the same evidentiary hurdles as the fraud claim.

4. The practical realities strongly favor a negotiated resolution. Lumos's limited cash position (approximately $390,000 post-refund), short operating runway (approximately 4.1 months at a $95,000/month burn rate), small team (14 employees), significant reputational concerns in the venture community, and the cascade effect on co-investors collectively render contested litigation an existentially threatening proposition for the Company. The costs and risks of litigation far outweigh any benefit that might be derived from asserting the Company's legal defenses in court.

5. Recommended course of action. We recommend that Lumos pursue a negotiated Mutual Termination & Release Agreement with Vantage Peak, and corresponding agreements with Ridgeline Angel Fund and Canopy Growth Capital, providing for:

(a) Full refund of the $3,500,000 SAFE purchase amount to Vantage Peak, and corresponding refunds of $1,200,000 to Ridgeline Angel Fund and $1,100,000 to Canopy Growth Capital;

(b) Mutual general releases by all parties of all claims, demands, actions, causes of action, liabilities, and obligations arising out of or relating to the SAFE financing round, the August 2023 pitch materials, and the events described herein;

(d) Mutual non-disparagement obligations prohibiting each party from making disparaging statements about the other in connection with the financing round or the resolution of the dispute; and

(e) Mutual confidentiality obligations regarding the terms of the resolution.

This approach eliminates litigation risk, preserves Lumos's reputation and relationships within the venture community, and allows the Company's management team to devote its full attention and limited resources to remediating the Prism Core v2.0 product issues. Per CTO Marsh's estimate, the product remediation effort will require 4 to 6 months; a clean resolution of the investor dispute positions the Company to pursue a new fundraising effort once the product has been validated and the beta milestone has been achieved.

6. Negotiation leverage. If Vantage Peak or its counsel insists on terms beyond a full refund and mutual release — for example, consequential damages, penalties, interest, legal fee reimbursement, or punitive provisions — Lumos should resist. The Company's contractual and equitable defenses, while not airtight, provide sufficient leverage to negotiate a clean mutual walk-away. A full refund with mutual releases is an equitable and commercially reasonable resolution that makes both parties whole. Demands for additional consideration beyond the refund amount are not supported by the strength of Vantage Peak's legal position and should be firmly but respectfully declined.

We are available to discuss this analysis at your convenience and to begin drafting the proposed Mutual Termination & Release Agreement upon authorization.

VI. REVIEW AND DISTRIBUTION

Prepared by:

________________________________________

Christy Bauer Associate, Calderwood & Harkness LLP

Date: October 17, 2023

Reviewed by:

________________________________________

Omar Siddiqui Associate, Calderwood & Harkness LLP

Date: ________

Reviewed by:

________________________________________

Patricia Dunmore Partner, Calderwood & Harkness LLP

Date: ________

Matter: Lumos Analytics Inc. — SAFE Financing Round

Matter No.: 1008-00003

DISTRIBUTION RESTRICTION: This memorandum is designated INTERNAL — ATTORNEY-CLIENT PRIVILEGED / ATTORNEY WORK PRODUCT. This document and its contents are privileged and confidential and are intended solely for the use of the attorneys and staff of Calderwood & Harkness LLP working on the referenced matter. This memorandum should not be distributed, forwarded, copied, or disclosed to any person or entity outside of Calderwood & Harkness LLP without the express prior written authorization of the supervising partner (Patricia Dunmore). Unauthorized disclosure may result in a waiver of applicable privileges.

Defense / Claim	Assessment	Risk Level
Common-law fraud	Colorable defense based on lack of scienter and heightened clear-and-convincing standard of proof; outcome is highly fact-dependent and turns on internal record regarding management's knowledge in August 2023	Moderate
Negligent misrepresentation	Weaker defense because claim does not require scienter, only failure to exercise reasonable care; lower preponderance-of-the-evidence standard; outcome depends on whether Lumos had a reasonable basis for the "beta-ready" projection	Moderate to High
Integration clause	Potentially effective against negligent misrepresentation if the SAFE contains specific non-reliance or disclaimer language; not effective against intentional fraud under Abry Partners and its progeny	Variable
Limitation-of-liability	Limited applicability given the standard form of the YC SAFE; not effective against intentional fraud claims; uncertain applicability to negligent misrepresentation	Limited
Rescission defense	Moderate risk; rescission is an equitable remedy within the court's discretion; however, the economic outcome (return of $3,500,000) is identical to the recommended negotiated refund	Moderate
Sophisticated investor defense	Supportive of Lumos's position on the justifiable reliance element, but not dispositive; sophisticated investors may still justifiably rely on specific factual representations within the counterparty's superior knowledge	Supportive but not dispositive

PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGED ATTORNEY WORK PRODUCT
MEMORANDUM
This memorandum is protected by the attorney-client privilege and the work product doctrine. It is intended solely for the use of Calderwood & Harkness LLP attorneys working on the referenced matter and our client, Lumos Analytics Inc. This memorandum should not be disclosed to any third party without the express prior authorization of the supervising partner.
FROM: Christy Bauer, Associate, Calderwood & Harkness LLP
TO: Omar Siddiqui, Associate; Patricia Dunmore, Partner
DATE: October 17, 2023
RE: Analysis of Potential Fraud and Misrepresentation Claims by Vantage Peak Ventures Fund II, L.P. Against Lumos Analytics Inc. Under Delaware Law
MATTER NO.: 1008-00003
CLIENT: Lumos Analytics Inc.
I. EXECUTIVE SUMMARY
This memorandum evaluates the merits, risks, and potential defenses available to our client, Lumos Analytics Inc. ("Lumos" or the "Company"), in connection with fraud and misrepresentation claims that Vantage Peak Ventures Fund II, L.P. ("Vantage Peak" or "VPV") may assert against Lumos arising from its $3,500,000 Post-Money Simple Agreement for Future Equity ("SAFE") executed on September 12, 2023.
The catalyst for this analysis is Vantage Peak's October 15, 2023 request for a return of its invested funds, followed by a formal withdrawal on October 18, 2023. On that date, Vantage Peak's counsel, Whitfield Harte & Associates LLP, transmitted a demand letter alleging that Lumos's August 2023 investor pitch materials contained a material misrepresentation regarding the readiness of Lumos's core technology product. Specifically, Whitfield Harte alleges that Lumos represented its machine-learning compliance scoring module, Prism Core v2.0, as "beta-ready by Q4 2023," and that this representation was materially false or misleading in light of a subsequent validation report prepared by Peralta IP Consulting LLC, dated October 9, 2023, which showed the module achieved only 61% accuracy against a required benchmark target of 92%.
After reviewing the relevant factual record, the applicable provisions of the executed SAFE, and the governing Delaware common law, I conclude as follows:
Lumos has colorable defenses under both the SAFE's contractual provisions (including its integration clause and the absence of express product-readiness representations and warranties) and Delaware common law (particularly on the scienter element of common-law fraud and the heightened clear-and-convincing evidentiary standard). However, the litigation risk remains meaningful for several reasons. First, the factual record on the scienter question — specifically, what Lumos's management knew or should have known about Prism Core v2.0's development trajectory in August 2023 — is ambiguous and has not been fully developed. Internal communications, development logs, and testing data could cut either way in discovery. Second, the negligent misrepresentation theory, which does not require scienter, presents a moderately higher level of exposure for the Company. Third, the practical and reputational harm of protracted litigation with a prominent venture capital fund would be disproportionate to the amount in controversy, particularly given Lumos's limited cash position, short operating runway, and small team.
Accordingly, the recommended course of action is to pursue a negotiated resolution in the form of a mutual termination of the SAFE with a full refund of the $3,500,000 purchase amount, accompanied by mutual general releases and mutual non-disparagement obligations. This approach eliminates litigation exposure, preserves the Company's reputation and relationships within the venture community, and allows management to focus its limited resources on remediating the underlying product issues.
This memorandum proceeds as follows: Part II sets forth the relevant factual background. Part III provides the legal analysis, addressing common-law fraud, negligent misrepresentation, contractual defenses, rescission, and statute of limitations considerations, as well as practical litigation risk factors. Part IV presents a summary assessment table. Part V states our conclusions and recommendations.
II. FACTUAL BACKGROUND
A. The Parties
Lumos Analytics Inc. Lumos is a Delaware C-corporation headquartered at 340 Folsom Street, Suite 1100, San Francisco, California 94105. The Company is a seed-stage enterprise software company operating in the SaaS/fintech vertical. Lumos's principal product is an AI-driven financial analytics platform marketed under the trade name "Lumos Prism," which is designed to provide automated compliance scoring and risk analytics for financial institutions. As of July 2023, the Company reported monthly recurring revenue ("MRR") of approximately $38,000, derived primarily from a small number of early-adopter enterprise customers and pilot programs. As of August 2023, the Company employed fourteen (14) full-time employees across engineering, product, sales, and administrative functions.
The Company's officers are as follows:
•  Priya Narasimhan — Co-Founder, Chief Executive Officer & President
•  Elliot Marsh — Co-Founder, Chief Technology Officer
•  Danielle Okoye — Chief Financial Officer (joined the Company in March 2023)
The Company's Board of Directors consists of three members:
•  Priya Narasimhan — Chair of the Board
•  Elliot Marsh — Director
•  Kenji Watanabe — Independent Director (appointed July 2023)
Vantage Peak Ventures Fund II, L.P. Vantage Peak is a Delaware limited partnership organized as a venture capital fund. Its general partner is Vantage Peak Capital Management LLC. Fund II is a 2022-vintage fund with total committed capital of approximately $185 million, focused on seed and early-stage investments in enterprise technology and financial services. The fund's managing partners are Catherine Aldridge and Raymond Petrov. The deal lead for the Lumos investment was Samantha Reyes, a Principal at the firm, who managed the diligence process and negotiated the SAFE terms on behalf of VPV.
Vantage Peak is represented in this matter by Whitfield Harte & Associates LLP, a Palo Alto-based law firm. The lead attorney is Jonathan Whitfield (Partner), with Megan Trost (Associate) serving as the primary day-to-day contact. Whitfield Harte is the firm that transmitted the October 18, 2023 demand letter on behalf of VPV.
B. The SAFE Financing Round
In the summer of 2023, Lumos initiated a fundraising round with a target of $6,800,000 in total investment, to be raised through Post-Money SAFEs based on the standard Calderon Partners LLC SAFE form, with certain modifications negotiated with investors. The key commercial terms of the SAFEs were as follows:
•  Post-money valuation cap: $28,000,000
•  discount: None
•  Form: Post-Money SAFE (YC standard form, modified)
Vantage Peak committed to investing $3,500,000 as the lead investor in the round. The Vantage Peak SAFE was executed on September 12, 2023. Funds in the amount of $3,500,000 were wired by Vantage Peak to Lumos's primary operating account at Silicon Valley Commerce Bank, Account Number 8801-4427-3390, on or about the date of execution.
Following the close of the Vantage Peak SAFE, three additional investors participated or expressed interest in the round:
1.  Ridgeline Angel Fund, L.P. — Committed $1,200,000 via a Post-Money SAFE executed and funded on September 22, 2023.
2.  Canopy Growth Capital LLC — Committed $1,100,000 via a Post-Money SAFE executed and funded on September 29, 2023.
3.  Atlas Fintech Syndicate, L.P. — Signed a term sheet on October 4, 2023 for $1,000,000, but the corresponding SAFE was never executed, and Atlas ultimately withdrew its interest following the events described below.
In total, $5,800,000 was funded into the round prior to the events giving rise to this dispute. The round did not reach its target of $6,800,000.
C. The Pitch Materials and Product Representations
In August 2023, Lumos prepared and circulated an investor pitch deck and related materials to Vantage Peak in connection with the fundraising round. These materials were subsequently provided, in substantially the same form, to the other investors participating in the round. The pitch deck included a product roadmap and technology overview section in which Lumos represented that its machine-learning compliance scoring module, denominated Prism Core v2.0, was "beta-ready by Q4 2023."
Prism Core v2.0 is the core differentiating technology underlying the Lumos Prism platform. It is a machine-learning model designed to score the compliance risk of financial transactions against a proprietary benchmark. The module is covered by U.S. Provisional Patent Application No. 63/987,214, filed on June 15, 2023, and represents the principal source of Lumos's claimed competitive advantage in its target market segment.
The "beta-ready by Q4 2023" representation was a central element of Lumos's investment thesis as presented to prospective investors. Vantage Peak's investment decision, as communicated by Samantha Reyes during the diligence process, was predicated in significant part on the expectation that Prism Core v2.0 would reach a functional beta release in the fourth quarter of 2023, enabling customer pilots and revenue acceleration in the first half of 2024.
These representations were made prior to the execution of the Vantage Peak SAFE on September 12, 2023, and were part of the inducement for Vantage Peak's investment decision. The same materials were also provided to Ridgeline, Canopy Growth, and Atlas prior to their respective commitments.
D. The Product Failure and Disclosure
On October 8, 2023, Peralta IP Consulting LLC, an independent technical consulting firm retained by Lumos to evaluate the performance of Prism Core v2.0, completed its functionality and accuracy validation testing of the module. The principal consultant responsible for the engagement was Dr. Amir Farouk, a specialist in machine-learning model validation.
On October 9, 2023, Peralta issued its formal validation report. The report concluded that Prism Core v2.0 achieved only 61% accuracy against the relevant compliance-scoring benchmark. The target accuracy threshold for the module to be considered beta-ready was 92%. The 31-percentage-point gap between actual and target performance represented a fundamental shortfall in the module's core functionality and indicated that the product was materially further from beta readiness than had been anticipated.
On October 10, 2023, CTO Elliot Marsh disclosed the Peralta validation results to the Lumos Board of Directors. During this disclosure, Marsh estimated that 4 to 6 months of additional development would be required to remediate the module's accuracy deficiencies and bring it to a state of beta readiness. This timeline implied that the earliest achievable beta launch would be in the range of February to April 2024, well beyond the "Q4 2023" timeframe represented in the August 2023 pitch materials.
On October 12, 2023, the Lumos Board of Directors convened a formal board meeting to discuss the Peralta report and its implications. The board determined that the Prism Core v2.0 failure constituted a material product setback with significant implications for the Company's business plan, revenue projections, and investor relations. The board debated the Company's disclosure obligations, including whether the information rights provisions of the executed SAFEs required prompt notification to investors, and ultimately authorized CEO Narasimhan to inform the lead investor.
On October 13, 2023, CEO Priya Narasimhan notified Vantage Peak's Samantha Reyes of the Peralta validation results and the estimated remediation timeline. This notification was the first communication to any investor regarding the product setback.
Key timeline gap. The pitch materials representing Prism Core v2.0 as "beta-ready by Q4 2023" were circulated in August 2023. At that time, the formal validation testing by Peralta had not yet been conducted — the testing was completed on October 8, 2023, approximately two months later. Whether Lumos's management had reason to know in August 2023 that the "beta-ready by Q4 2023" representation was unreliable, unsupported, or at risk of being inaccurate is a contested factual question that lies at the heart of the scienter inquiry discussed in Part III below.
E. Vantage Peak's Withdrawal and Demand
On October 15, 2023 — two days after receiving notification of the product setback — Vantage Peak communicated to Lumos a request for the return of its invested funds, citing alleged material misrepresentation regarding product readiness as the basis for the request.
On October 18, 2023, Vantage Peak formalized its withdrawal from the SAFE. On the same date, Lumos received a demand letter from Whitfield Harte & Associates LLP, acting as counsel for Vantage Peak. The demand letter asserted claims of fraud and material misrepresentation under Delaware law, and demanded a full refund of the $3,500,000 SAFE purchase amount. The demand letter specifically referenced the August 2023 pitch materials, the "beta-ready by Q4 2023" representation, and the Peralta validation report as the basis for Vantage Peak's claims.
Following Vantage Peak's withdrawal, the remaining funded investors — Ridgeline Angel Fund and Canopy Growth Capital — also initiated communications regarding their own rights and potential withdrawal. Atlas Fintech Syndicate, whose SAFE was never executed, withdrew its expression of interest entirely. The cascade effect of these developments is discussed further in Part III.F below.
III. LEGAL ANALYSIS
A. Common-Law Fraud Under Delaware Law
1. Elements of the Claim.  Under Delaware law, a plaintiff asserting a claim for common-law fraud must establish each of the following five elements:
(a) A false representation, usually of fact, made by the defendant to the plaintiff;
(b) The defendant's knowledge or belief that the representation was false, or that the representation was made with reckless indifference to its truth or falsity (scienter);
(c) An intent to induce the plaintiff to act or refrain from acting in reliance upon the representation;
(d) The plaintiff's action or inaction was taken in justifiable reliance on the representation; and
(e) The plaintiff suffered damage as a proximate result of such reliance.
See Stephenson v. Capano Dev., Inc., 462 A.2d 1069, 1074 (Del. 1983); Gaffin v. Teledyne, Inc., 611 A.2d 467, 472 (Del. 1992); Trenwick Am. Litig. Trust v. Rowan Whitfield CPAs LLP, L.L.P., 906 A.2d 168, 207 (Del. Ch. 2006), aff'd, 931 A.2d 438 (Del. 2007).
Critically, Delaware law imposes a heightened standard of proof for fraud claims. Unlike most civil claims, which are decided on a preponderance-of-the-evidence standard, a fraud plaintiff must prove each element by clear and convincing evidence. See Stephenson, 462 A.2d at 1074; Metro Commc'n Corp. BVI v. Advanced Mobilecomm Techs. Inc., 854 A.2d 121, 131 (Del. Ch. 2004). This heightened evidentiary burden is a significant factor in assessing Lumos's litigation exposure, as discussed below.
2. Application to Lumos's Representations.  Each element of the fraud analysis is addressed in turn.
a. False Representation
The threshold question is whether the "beta-ready by Q4 2023" statement in the August 2023 pitch materials constitutes a "false representation of fact" within the meaning of Delaware fraud law. Vantage Peak will argue that this was an objectively false representation regarding the readiness of Prism Core v2.0, as conclusively demonstrated by the Peralta validation report's finding of only 61% accuracy against a 92% target. On its face, the magnitude of the shortfall — a 31-percentage-point gap — suggests that the product was not merely behind schedule but was fundamentally not in a condition to achieve beta readiness within the represented timeframe.
Lumos has a counter-argument on this element. At the time the representation was made — August 2023 — the formal validation testing by Peralta had not yet been conducted. That testing was not completed until October 8, 2023, nearly two months after the pitch materials were circulated. Accordingly, Lumos can argue that the "beta-ready by Q4 2023" statement was a good-faith, forward-looking projection based on the information available to management at the time, not a statement of present fact. Under Delaware law, expressions of opinion, statements of belief, and forward-looking projections are generally not actionable as fraud unless the speaker did not genuinely hold the stated opinion or belief at the time the statement was made. See In re IBP, Inc. S'holders Litig., 789 A.2d 14, 68–69 (Del. Ch. 2001).
However, this distinction is not dispositive. Delaware courts have recognized that a statement characterized as a "projection" or "estimate" may nonetheless be actionable if it implies a present factual basis — for example, if it implies that the speaker has conducted sufficient analysis to support the projection and no information available to the speaker is materially inconsistent with it. See Ams. Mining Corp. v. Theriault, 51 A.3d 1213, 1239 (Del. 2012). The "beta-ready by Q4 2023" representation, while nominally forward-looking, implicitly represents that the product's development trajectory as of August 2023 supported the stated timeline. If the facts available to management at that time did not support such a trajectory, the representation could be deemed a misstatement of present fact (i.e., a misstatement about the product's current development status and the reasonableness of the projected timeline).
In sum, the false-representation element is contested but arguable for both sides. The resolution will depend heavily on the factual record regarding what information was available to Lumos's management in August 2023.
b. Scienter
Scienter is the most critical and debatable element of the fraud claim. To satisfy scienter, Vantage Peak must prove by clear and convincing evidence that Lumos's management — specifically, CEO Priya Narasimhan and CTO Elliot Marsh, who were primarily responsible for the pitch materials and the product roadmap — either (i) knew the "beta-ready by Q4 2023" representation was false when it was made, or (ii) made the representation with reckless indifference to its truth or falsity.
The central factual question is: What did CTO Marsh and CEO Narasimhan know or have reason to know in August 2023 about Prism Core v2.0's development trajectory? Specifically:
(i) What internal development milestones and testing data were available to Marsh and Narasimhan before August 2023? Were there interim accuracy benchmarks, prototype test runs, or internal validation metrics that indicated the module's performance trajectory?
(ii) Were there any internal communications — emails, Meridian Solutions messages, engineering reports, sprint retrospectives, or board memoranda — that indicated the 92% accuracy target was at risk or that the Q4 2023 beta timeline was not achievable?
(iii) What was the factual basis for the "beta-ready by Q4 2023" projection? Was it derived from a documented engineering roadmap with identified milestones, or was it an aspirational target without a concrete technical foundation?
If the evidence shows that Lumos's management genuinely believed in August 2023 that the Q4 2023 beta timeline was achievable — based on the development data then available — then scienter is lacking. A good-faith belief that later proves incorrect is not fraud, even if the belief turns out to have been overly optimistic. See Prairie Capital III, L.P. v. Double E Holding Corp., 132 A.3d 35, 50–51 (Del. Ch. 2015) (noting that fraud requires more than a statement that turns out to be inaccurate; the plaintiff must show that the defendant knew or recklessly disregarded the falsity at the time of the statement).
Conversely, if internal evidence shows early warning signs that were ignored or suppressed — for example, if internal test results from July or early August 2023 showed accuracy rates well below the 92% target, or if engineering team members raised concerns about the feasibility of the Q4 timeline that were overridden by management — then the scienter analysis becomes significantly more adverse for Lumos. In that scenario, Vantage Peak could argue that management knew the representation was false or, at minimum, made it with reckless indifference to the risk that the product would not achieve the stated milestone.
We have not yet had the opportunity to conduct a thorough review of Lumos's internal communications and development records from the relevant period. This review is critical and should be prioritized. I recommend that we immediately issue a litigation hold notice to Lumos and request the preservation and production of all internal communications, development logs, testing data, engineering reports, and board materials from June through September 2023 related to Prism Core v2.0's development status and the "beta-ready" timeline. This evidence will be determinative of the scienter question and, by extension, of the overall strength of the fraud claim.
c. Intent to Induce
This element is likely satisfied and will be difficult for Lumos to contest. The August 2023 pitch materials were expressly created and circulated for the purpose of soliciting investment in Lumos. The "beta-ready by Q4 2023" representation was included in the product roadmap section of the pitch deck, which is a standard component of investor solicitation materials designed to communicate the company's value proposition and development trajectory. There is no credible argument that the pitch materials were prepared for any purpose other than inducing prospective investors to commit capital. Accordingly, this element does not present a meaningful line of defense.
d. Justifiable Reliance
The justifiable reliance element requires analysis of whether Vantage Peak's reliance on the "beta-ready by Q4 2023" representation was reasonable under the circumstances. This analysis is informed by the sophistication of the parties and the nature of the representation.
Vantage Peak is a sophisticated institutional investor. It operates a $185 million venture capital fund, employs experienced investment professionals (including a dedicated deal lead, Samantha Reyes, who is a Principal at the firm), and is represented by established counsel (Whitfield Harte & Associates LLP). Delaware courts apply a reasonableness standard to the reliance element and generally hold that sophisticated parties with access to information and the resources to conduct independent diligence bear a greater burden in establishing justifiable reliance. See Siga Techs., Inc. v. PharmAthene, Inc., 67 A.3d 330, 348 (Del. 2013); Great Lakes Chem. Corp. v. Pharmacia Corp., 788 A.2d 544, 555 (Del. Ch. 2001).
Lumos can argue that Vantage Peak, as a sophisticated venture capital fund with extensive experience in seed-stage technology investments, was in a position to — and should have — independently validated Prism Core v2.0's technical readiness prior to executing the SAFE. The fact that Vantage Peak did not commission its own independent technical assessment of the module's development status weighs against a finding of justifiable reliance. Sophisticated investors are expected to "protect themselves" and cannot blindly rely on a startup's pitch deck without conducting their own diligence. See RAA Mgmt., LLC v. Savage Sports Holdings, Inc., 45 A.3d 107, 118–19 (Del. 2012).
However, this argument has limits. Delaware law recognizes that even sophisticated parties may justifiably rely on specific factual representations made by the counterparty, particularly where those representations relate to matters within the counterparty's superior knowledge or control. See Airborne Health, Inc. v. Squid Soap, LP, 984 A.2d 126, 143–44 (Del. Ch. 2009). The development status of Prism Core v2.0 was a matter squarely within Lumos's knowledge and control; Vantage Peak had no independent access to the module's source code, internal testing data, or engineering roadmap. The "beta-ready by Q4 2023" representation was a specific, time-bound statement about a concrete product milestone, not a vague expression of optimism. A court could reasonably conclude that reliance on such a representation was justified, even by a sophisticated investor, given the informational asymmetry inherent in early-stage venture investments.
Additionally, the fact that Vantage Peak did not independently validate the product's technical readiness is not unusual in the context of seed-stage SAFE investments, where the speed and informality of the fundraising process often preclude the kind of exhaustive technical diligence that might be expected in a later-stage preferred stock round with full representations and warranties.
On balance, the reliance element is contested but not clearly in Lumos's favor. The sophisticated-investor defense is supportive but likely not dispositive, particularly given the specificity of the representation and the informational asymmetry.
e. Damages
If Vantage Peak succeeds on a fraud claim, the measure of damages would be the return of the $3,500,000 SAFE purchase amount — i.e., the amount of the investment that was induced by the alleged misrepresentation. Vantage Peak might also seek consequential damages, which could include the opportunity cost of deploying the $3,500,000 elsewhere during the investment period, as well as due diligence expenses, legal fees, and related costs incurred in connection with the Lumos investment and the subsequent dispute.
More likely, however, Vantage Peak would seek rescission of the SAFE as the primary remedy, which would restore both parties to the pre-investment status quo. The rescission remedy is discussed separately in Part III.D below.
3. Assessment of Lumos's Exposure on Common-Law Fraud.  In summary, the scienter element is the primary battleground on the common-law fraud claim. Lumos has a reasonable argument that the August 2023 representations were good-faith, forward-looking statements based on the information available to management at the time, and that the subsequent product failure was an unforeseen development that does not give rise to an inference of fraud.
However, several factors complicate this defense:
•  The gap between actual performance (61%) and the target threshold (92%) is substantial — a 31-percentage-point shortfall. This magnitude raises a natural inference that the product was far from beta-ready even at the time the representation was made, which could undermine the claim that management's belief in the Q4 timeline was reasonable.
•  The factual record on what management knew in August 2023 is undeveloped. Until we review the internal communications and development data, we cannot assess with confidence whether the good-faith defense will hold.
•  While the heightened clear-and-convincing standard of proof benefits Lumos, it is not an impenetrable shield — particularly if the internal evidence is adverse.
Overall risk assessment on common-law fraud: MODERATE. The claim is viable but faces significant hurdles on scienter and the standard of proof. The outcome is highly fact-dependent and will be determined largely by what the internal record reveals.
B. Negligent Misrepresentation Under Delaware Law
1. Elements of the Claim.  Delaware law recognizes a cause of action for negligent misrepresentation. The elements are as follows:
(a) The defendant owed a pecuniary duty to provide accurate information to the plaintiff (or the defendant had a pecuniary interest in the transaction);
(b) The defendant supplied false information to the plaintiff;
(c) The defendant failed to exercise reasonable care in obtaining or communicating the information; and
(d) The plaintiff justifiably relied on the information and suffered pecuniary loss as a result.
See Outdoor Techs., Inc. v. Allfirst Fin., Inc., 2001 WL 541472, at 5 (Del. Super. Ct. Apr. 24, 2001); Guardian Constr. Co. v. Tetra Tech Richardson, Inc.*, 583 A.2d 1378, 1386 (Del. Super. Ct. 1990).
The critical distinction between negligent misrepresentation and common-law fraud is the absence of a scienter requirement. A negligent misrepresentation claim does not require proof that the defendant knew the information was false or acted with reckless indifference to the truth. Instead, the plaintiff need only show that the defendant failed to exercise reasonable care in obtaining or communicating the information. The standard of proof is also lower: negligent misrepresentation requires proof by a preponderance of the evidence, not the heightened clear-and-convincing standard applicable to fraud.
2. Application to Lumos's Representations.  Pecuniary duty. Lumos owed a duty of reasonable care in providing information to prospective investors in connection with the fundraising round. The circulation of investor pitch materials is a classic context in which this duty arises. The August 2023 pitch deck was prepared for the specific purpose of soliciting investment capital, and Lumos had a direct pecuniary interest in the accuracy of the information conveyed to investors. This element is straightforwardly satisfied.
False information. For the same reasons discussed in Part III.A.2.a above, Vantage Peak will argue that the "beta-ready by Q4 2023" representation was false. The analysis of this element is the same as for the fraud claim.
Failure to exercise reasonable care. This is the key element for the negligent misrepresentation theory, and it is where Vantage Peak's case is meaningfully stronger than its fraud case. The question is not whether Lumos knew the representation was false (scienter), but whether Lumos exercised reasonable care in formulating and communicating the "beta-ready by Q4 2023" projection.
Vantage Peak will likely argue that Lumos failed to exercise reasonable care by representing a specific product readiness timeline to investors without first conducting adequate internal validation or testing to confirm that the timeline was achievable. The fact that formal validation testing (by Peralta) was not completed until October 8, 2023 — nearly two months after the pitch materials were circulated — suggests that the "beta-ready by Q4 2023" representation may have been made without a sufficiently rigorous empirical foundation. If Lumos's management projected beta readiness by Q4 2023 without having validated the module's accuracy against the target benchmark, a court could find that the Company failed to exercise the level of care that a reasonable person in similar circumstances would have exercised in communicating such a representation to investors.
Lumos's defense on this element would be that the projection was based on the engineering team's assessment of the product's development trajectory, informed by internal milestones and engineering judgment, and that it was not unreasonable to rely on this assessment without first completing formal third-party validation. The strength of this defense depends, again, on the internal factual record — specifically, whether there was a reasonable basis for the engineering team's assessment in August 2023 and whether any internal data suggested the 92% target was at risk.
Justifiable reliance. The reliance analysis for negligent misrepresentation is substantially the same as for fraud. However, Delaware courts may be somewhat more lenient in finding reliance reasonable in the negligent misrepresentation context, particularly where the representation relates to matters within the defendant's superior knowledge. The sophisticated-investor defense remains relevant but may carry less weight.
Risk assessment on negligent misrepresentation: MODERATE TO HIGH. The absence of a scienter requirement and the lower preponderance-of-the-evidence standard make this theory a more accessible avenue for Vantage Peak. Lumos's exposure is meaningfully higher on negligent misrepresentation than on common-law fraud. The outcome hinges on whether Lumos can demonstrate that it had a reasonable basis for the "beta-ready" statement and exercised due care in formulating the projection.
C. Contractual Defenses: The SAFE's Limitation-of-Liability and Integration Clauses
1. Integration Clause.  The executed SAFE between Lumos and Vantage Peak contains a standard integration (or merger) clause providing that the SAFE constitutes the entire agreement between the parties with respect to the subject matter thereof and supersedes all prior negotiations, representations, warranties, and agreements, whether written or oral.
Argument for Lumos. Lumos can argue that the integration clause bars Vantage Peak from relying on the pre-contractual August 2023 pitch representations as the basis for a misrepresentation claim. Under this theory, by executing the SAFE with an integration clause, Vantage Peak acknowledged that its rights and obligations vis-à-vis Lumos are governed exclusively by the terms of the SAFE itself, and that any representations or promises made outside the four corners of the SAFE are merged into the agreement and have no independent legal effect. The investor's remedies are limited to those set forth in the SAFE, which does not provide a right to a refund based on pre-contractual representations.
Counter-argument. Under well-established Delaware law, an integration clause does not bar claims for fraudulent inducement. A party cannot contractually insulate itself from liability for fraud in the inducement, because a contract procured by fraud is voidable at the election of the defrauded party. See Abry Partners V, L.P. v. F & W Acquisition LLC, 891 A.2d 1032, 1059 (Del. Ch. 2006) ("[A] party cannot contractually immunize itself from liability for making affirmative misrepresentations of fact that constitute fraud."); RAA Mgmt., LLC, 45 A.3d at 119.
However, the integration clause may have greater force with respect to a negligent misrepresentation claim. If the SAFE contains not merely a generic integration clause but also a specific non-reliance or disclaimer-of-representations clause — sometimes referred to as a "big-boy" provision — in which Vantage Peak expressly represents that it has not relied on any representations or statements by Lumos other than those set forth in the SAFE, this could significantly limit Vantage Peak's ability to assert a negligent misrepresentation claim based on extra-contractual statements. See Abry Partners, 891 A.2d at 1058 (holding that a contractual representation that the buyer "did not rely on any representation, statement, or agreement other than those expressly set forth in this Agreement" can bar claims for negligent or innocent misrepresentation, though not for intentional fraud); IOTEX Commc'ns, Inc. v. Defries, 1998 WL 914265, at *3 (Del. Ch. Dec. 21, 1998).
Analysis of the Vantage Peak SAFE. We need to carefully review the specific language of the integration clause in the executed SAFE, as well as any accompanying disclaimer or non-reliance provisions. The standard YC Post-Money SAFE form includes a relatively brief integration clause but does not typically include a robust "big-boy" or express non-reliance representation. If the modifications negotiated with Vantage Peak included the addition of such a clause, Lumos's position on the negligent misrepresentation claim would be materially strengthened. If no such clause was added — which is the more likely scenario given the typical dynamics of a seed-stage SAFE negotiation — the integration clause alone will provide limited protection.
I recommend that we obtain and review the fully executed SAFE, with all modifications, to determine the precise scope of the integration clause and whether any non-reliance language was included.
2. Limitation-of-Liability Provisions.  We should also analyze whether the SAFE contains any limitation-of-liability provisions or caps on damages that could limit Lumos's exposure in the event of a successful claim.
The standard YC Post-Money SAFE form does not include extensive limitation-of-liability provisions. The SAFE is a relatively streamlined instrument that defines the investor's rights primarily in terms of conversion mechanics upon the occurrence of specified triggering events (equity financing, liquidity event, dissolution). However, the modified form used in this transaction should be reviewed for any negotiated additions. It is possible that during the negotiation process, one or both parties sought to include provisions addressing liability, indemnification, or exclusive remedies.
If the SAFE limits the investor's remedies to the return of the purchase amount upon a Dissolution Event — which is a standard feature of the YC SAFE form — Lumos may argue that this exclusive remedy structure preempts extra-contractual damage claims. Under this theory, the SAFE establishes a comprehensive framework for the investor's recovery rights, and claims seeking relief beyond that framework (such as consequential damages, opportunity costs, or punitive damages) are not available.
Counter-argument. Limitation-of-liability clauses are generally not enforceable against claims of intentional fraud under Delaware law. A party cannot contractually limit its liability for its own deliberate wrongdoing. See SIGA Techs., 67 A.3d at 348. Accordingly, even if the SAFE contains a limitation-of-liability provision, it would not protect Lumos against a successful fraud claim.
With respect to negligent misrepresentation, the enforceability of a limitation-of-liability clause is more nuanced and would depend on the specific language of the provision. A broadly drafted limitation that encompasses "all claims arising out of or relating to this Agreement" might extend to negligent misrepresentation claims, while a narrower provision limited to breaches of the SAFE's own terms might not.
Assessment: The limitation-of-liability defense is of limited utility given the standard form of the YC SAFE and the inapplicability of such provisions to intentional fraud claims.
3. Absence of Express Representations and Warranties in the SAFE.  Unlike a preferred stock purchase agreement or a traditional securities purchase agreement, the standard Post-Money SAFE does not contain extensive representations and warranties by the issuer regarding the company's business, financial condition, intellectual property, product development, or technology. The YC SAFE form is intentionally minimalist in this regard, reflecting the instrument's design as a lightweight, founder-friendly financing mechanism for early-stage companies.
This absence of contractual representations cuts both ways:
(a) Argument for Lumos. Lumos can argue that Vantage Peak, as a sophisticated investor represented by experienced counsel, accepted the SAFE with full awareness that the instrument contained no product-readiness warranty or representation. By choosing to invest via a SAFE — as opposed to a preferred stock round with full representations and warranties, indemnification obligations, and closing conditions — Vantage Peak assumed the inherent risks associated with a less-protective investment structure. The absence of a contractual product-readiness warranty indicates that Vantage Peak was willing to bear the risk that the product might not achieve the milestones discussed in the pitch materials, or at minimum, that it did not deem such a warranty important enough to negotiate for.
(b) Argument for Vantage Peak. Conversely, Vantage Peak can argue that the absence of contractual representations and warranties in the SAFE means that it was entitled to rely on the extra-contractual representations made in the pitch materials, precisely because there were no contractual representations to supersede or displace them. In other words, the SAFE does not contain an express warranty regarding product readiness, but neither does it contain a disclaimer or non-reliance clause negating the pitch representations. In the absence of such contractual provisions, the pre-contractual representations retain their independent legal significance, and Vantage Peak was justified in relying on them.
This issue is closely related to the integration clause analysis discussed above. The resolution depends on the overall structure of the SAFE, the presence or absence of non-reliance language, and the court's assessment of the reasonable expectations of the parties in the context of a seed-stage SAFE financing.
D. Potential Rescission Claim
In addition to (or in lieu of) a claim for money damages, Vantage Peak may seek rescission of the SAFE on equitable grounds. Rescission is the unwinding of a contract and the restoration of the parties to the positions they occupied prior to entering into the agreement.
Under Delaware law, a court may grant rescission where a contract was induced by material misrepresentation (whether fraudulent or negligent), or where there is a mutual mistake regarding a basic assumption underlying the contract. See Restatement (Second) of Contracts §§ 152, 164 (1981); see also Hollowell Private Capital Int'l, Ltd. v. Apollo Mgmt., L.P., 794 A.2d 1141, 1151 (Del. 2002); BAE Sys. Info. & Elec. Sys. Integration, Inc. v. Harborline Industries, 2009 WL 264088, at *6 (Del. Ch. Feb. 3, 2009).
If rescission is granted, the remedy would be the return of the $3,500,000 purchase amount to Vantage Peak, and the cancellation of the SAFE and all rights thereunder. This is the same economic outcome that would result from a negotiated mutual termination and refund.
Rescission is an equitable remedy and is within the court's discretion. In exercising this discretion, Delaware courts weigh the equities of the situation, including the promptness of the plaintiff's claim (whether the plaintiff acted with reasonable diligence upon discovering the alleged misrepresentation), the ability to restore the parties to the status quo ante, whether monetary damages are an adequate alternative remedy, and whether the plaintiff has unclean hands or is otherwise estopped from seeking equitable relief. See Cantera v. Harborline Corporation Senior Living Servs., Inc., 1999 WL 118823, at *5 (Del. Ch. Feb. 18, 1999).
Here, Vantage Peak acted promptly upon learning of the product setback — requesting a return of funds on October 15, 2023, just two days after receiving notice on October 13, 2023. The status quo ante is readily restorable: the transaction was a simple cash-for-SAFE exchange, and the funds can be returned without significant unwinding complications. These factors favor rescission.
Risk assessment: MODERATE. The economic outcome of rescission is identical to the recommended negotiated resolution (full refund). Accordingly, the risk of a rescission award does not independently increase Lumos's total financial exposure; rather, it reinforces the pragmatic case for a negotiated refund on consensual terms.
E. Statute of Limitations Considerations
Under Delaware law, the statute of limitations for fraud claims is three years from the date of the wrongful act or, under the discovery rule, from the date the plaintiff knew or should have known of the facts giving rise to the claim. 10 Del. C. § 8106.
Vantage Peak learned of the Prism Core v2.0 product failure on October 13, 2023, when CEO Narasimhan provided notification. Vantage Peak transmitted its demand letter on October 18, 2023, and any litigation would presumably be filed in the near term. Any claim filed within this timeframe would be well within the three-year limitations period, and the statute of limitations is not a practical defense at this stage of the dispute.
We note this issue for completeness and to confirm that any delay in resolving the dispute does not implicate limitations concerns for Lumos's own potential counterclaims or cross-claims, should such claims become relevant.
F. Litigation Risk and Practical Considerations
Beyond the doctrinal legal analysis, several practical factors bear significantly on the risk assessment and the recommended course of action.
1. Factual Uncertainty on Scienter.  As discussed at length in Part III.A.2.b, the strength of Lumos's defense to the common-law fraud claim depends critically on the internal factual record regarding what CTO Marsh and CEO Narasimhan knew about Prism Core v2.0's development status in August 2023. This factual record has not yet been fully developed or reviewed by outside counsel.
This factual uncertainty creates a dual-edged litigation risk:
•  If discovery reveals that the internal record supports a good-faith defense — i.e., that management had a reasonable basis for the "beta-ready by Q4 2023" projection and was not aware of any data suggesting the 92% accuracy target was at risk — then Lumos's litigation position is strong, and Vantage Peak would face significant difficulty establishing scienter by clear and convincing evidence.
•  If, however, discovery reveals adverse internal communications — for example, emails or Meridian Solutions messages in which engineering team members expressed skepticism about the Q4 timeline, internal test results showing accuracy rates substantially below 92%, or evidence that management was aware of risk factors that were not disclosed to investors — then Lumos's position would be materially weakened, and the scienter element could be established.
Litigation would necessarily involve extensive document discovery of Lumos's internal communications, development logs, project management records (e.g., JIRA or equivalent tools), testing data, board materials, and executive communications from the June through September 2023 period. This discovery process would be invasive, time-consuming, and distracting for a 14-person startup, and it carries the inherent risk that the internal record may contain unfavorable evidence that management has not yet surfaced to outside counsel.
2. Reputational Impact.  Vantage Peak Ventures is a prominent early-stage venture fund with a $185 million fund, a well-known brand in the technology venture community, and extensive relationships with other investors, portfolio companies, and industry participants. Litigation with a well-known VC firm — particularly on fraud allegations — would almost certainly become known within the venture ecosystem and would likely damage Lumos's ability to raise future capital. Prospective investors in any future fundraising round would conduct background diligence and would inevitably discover the pending or resolved fraud litigation. The reputational stain of fraud allegations, even if ultimately unfounded, could effectively disqualify Lumos from raising institutional venture capital for an extended period.
Even if Lumos ultimately prevails in litigation, the cost of defense — both in financial terms and in terms of management time and attention — would be existentially threatening to a seed-stage company. As of the current date, assuming a full refund of all investor funds ($5,800,000), Lumos's cash position would be reduced to approximately $390,000, reflecting roughly $30,000 in net operating expenses and legal fees incurred during the round period. At the Company's current monthly burn rate of approximately $95,000, this cash position provides only approximately 4.1 months of operating runway. Litigation defense costs — including outside counsel fees, expert witnesses, e-discovery vendors, and related expenses — could easily consume the Company's entire cash reserve within the first few months of active litigation, forcing the Company to seek emergency financing or cease operations.
3. Cascade Effect on Co-Investors.  Vantage Peak's withdrawal has already triggered a cascade effect among the other investors in the round:
•  Ridgeline Angel Fund, L.P. ($1,200,000 funded) has communicated its intent to seek a return of funds.
•  Canopy Growth Capital LLC ($1,100,000 funded) has similarly indicated that it is evaluating its rights and may seek withdrawal.
•  Atlas Fintech Syndicate, L.P. ($1,000,000 term sheet signed, SAFE never executed) has withdrawn its interest entirely and will not be proceeding with the investment.
Protracted litigation with Vantage Peak would further erode investor and market confidence, potentially making it impossible for Lumos to retain the Ridgeline and Canopy Growth investments even if those investors might otherwise have been willing to remain in the round. The cascade effect also creates the risk of additional claims by Ridgeline and Canopy Growth, who received substantially the same pitch materials and could assert similar fraud and misrepresentation theories.
4. Cost-Benefit Analysis: Litigation vs. Negotiated Resolution.  The foregoing considerations strongly favor a negotiated resolution over contested litigation. The cost-benefit analysis may be summarized as follows:
•  A full refund of $3,500,000 to Vantage Peak (or $5,800,000 across all funded investors) restores the parties to the pre-round status quo. This is the same economic outcome that would result from a successful rescission claim by Vantage Peak.
•  Lumos's pre-round cash position was approximately $420,000. After accounting for approximately $30,000 in net operating expenses and legal fees during the round period, the post-refund cash position would be approximately $390,000.
•  Litigation defense costs — including outside counsel fees, e-discovery, expert retention, and related expenses — would quickly exceed the Company's available cash resources. A contested fraud litigation through summary judgment alone could cost $500,000 to $1,000,000 or more, far exceeding the Company's entire cash reserve.
•  A mutual termination with full refund and mutual general releases eliminates ongoing legal exposure, avoids the risk of an adverse judgment (which could include consequential damages in addition to the refund amount), and preserves the option to pursue future fundraising once the Prism Core v2.0 product issues are remediated.
In short, the economic outcome of the most likely litigation result (rescission and refund) is identical to the proposed negotiated outcome, but litigation adds substantial cost, delay, risk, and reputational damage. The negotiated resolution is clearly the superior course of action from a risk-management perspective.
IV. ASSESSMENT OF LUMOS'S DEFENSES — SUMMARY TABLE
The following table summarizes the assessment of each potential defense and the corresponding level of litigation risk:
V. CONCLUSION AND RECOMMENDATION
Based on the foregoing analysis, I conclude and recommend as follows:
1. Lumos has colorable but not airtight defenses to Vantage Peak's potential fraud and misrepresentation claims. The Company is not without arguments — the scienter element of the fraud claim is genuinely contested, the heightened standard of proof provides meaningful protection, and the sophisticated-investor defense and the SAFE's integration clause offer additional (if limited) support. However, none of these defenses is sufficiently strong to warrant confidence that Lumos would prevail in contested litigation.
2. The scienter element is fact-intensive and uncertain. The resolution of the fraud claim turns on what Lumos's management knew about Prism Core v2.0's development trajectory in August 2023. Until the internal factual record is fully reviewed, we cannot assess with confidence whether the good-faith defense will withstand scrutiny. Discovery could produce evidence that either supports or undermines Lumos's position, and the risk of adverse findings is real.
3. The negligent misrepresentation claim presents higher exposure than the fraud claim because it does not require scienter — only a failure to exercise reasonable care. Given the apparent absence of formal validation testing prior to the circulation of the pitch materials, Vantage Peak has a credible argument that Lumos failed to exercise due care in representing a specific product readiness timeline to investors. This claim is subject to the lower preponderance-of-the-evidence standard and does not face the same evidentiary hurdles as the fraud claim.
4. The practical realities strongly favor a negotiated resolution. Lumos's limited cash position (approximately $390,000 post-refund), short operating runway (approximately 4.1 months at a $95,000/month burn rate), small team (14 employees), significant reputational concerns in the venture community, and the cascade effect on co-investors collectively render contested litigation an existentially threatening proposition for the Company. The costs and risks of litigation far outweigh any benefit that might be derived from asserting the Company's legal defenses in court.
5. Recommended course of action. We recommend that Lumos pursue a negotiated Mutual Termination & Release Agreement with Vantage Peak, and corresponding agreements with Ridgeline Angel Fund and Canopy Growth Capital, providing for:
(a) Full refund of the $3,500,000 SAFE purchase amount to Vantage Peak, and corresponding refunds of $1,200,000 to Ridgeline Angel Fund and $1,100,000 to Canopy Growth Capital;
(b) Mutual general releases by all parties of all claims, demands, actions, causes of action, liabilities, and obligations arising out of or relating to the SAFE financing round, the August 2023 pitch materials, and the events described herein;
(c) No admission of liability by any party;
(d) Mutual non-disparagement obligations prohibiting each party from making disparaging statements about the other in connection with the financing round or the resolution of the dispute; and
(e) Mutual confidentiality obligations regarding the terms of the resolution.
This approach eliminates litigation risk, preserves Lumos's reputation and relationships within the venture community, and allows the Company's management team to devote its full attention and limited resources to remediating the Prism Core v2.0 product issues. Per CTO Marsh's estimate, the product remediation effort will require 4 to 6 months; a clean resolution of the investor dispute positions the Company to pursue a new fundraising effort once the product has been validated and the beta milestone has been achieved.
6. Negotiation leverage. If Vantage Peak or its counsel insists on terms beyond a full refund and mutual release — for example, consequential damages, penalties, interest, legal fee reimbursement, or punitive provisions — Lumos should resist. The Company's contractual and equitable defenses, while not airtight, provide sufficient leverage to negotiate a clean mutual walk-away. A full refund with mutual releases is an equitable and commercially reasonable resolution that makes both parties whole. Demands for additional consideration beyond the refund amount are not supported by the strength of Vantage Peak's legal position and should be firmly but respectfully declined.
We are available to discuss this analysis at your convenience and to begin drafting the proposed Mutual Termination & Release Agreement upon authorization.
VI. REVIEW AND DISTRIBUTION
Prepared by:
________________________________________
Christy Bauer Associate, Calderwood & Harkness LLP
Date: October 17, 2023
Reviewed by:
________________________________________
Omar Siddiqui Associate, Calderwood & Harkness LLP
Date: ________
Reviewed by:
________________________________________
Patricia Dunmore Partner, Calderwood & Harkness LLP
Date: ________
Matter: Lumos Analytics Inc. — SAFE Financing Round
Matter No.: 1008-00003
DISTRIBUTION RESTRICTION: This memorandum is designated INTERNAL — ATTORNEY-CLIENT PRIVILEGED / ATTORNEY WORK PRODUCT. This document and its contents are privileged and confidential and are intended solely for the use of the attorneys and staff of Calderwood & Harkness LLP working on the referenced matter. This memorandum should not be distributed, forwarded, copied, or disclosed to any person or entity outside of Calderwood & Harkness LLP without the express prior written authorization of the supervising partner (Patricia Dunmore). Unauthorized disclosure may result in a waiver of applicable privileges.
Defense / Claim | Assessment | Risk Level
Common-law fraud | Colorable defense based on lack of scienter and heightened clear-and-convincing standard of proof; outcome is highly fact-dependent and turns on internal record regarding management's knowledge in August 2023 | Moderate
Negligent misrepresentation | Weaker defense because claim does not require scienter, only failure to exercise reasonable care; lower preponderance-of-the-evidence standard; outcome depends on whether Lumos had a reasonable basis for the "beta-ready" projection | Moderate to High
Integration clause | Potentially effective against negligent misrepresentation if the SAFE contains specific non-reliance or disclaimer language; not effective against intentional fraud under Abry Partners and its progeny | Variable
Limitation-of-liability | Limited applicability given the standard form of the YC SAFE; not effective against intentional fraud claims; uncertain applicability to negligent misrepresentation | Limited
Rescission defense | Moderate risk; rescission is an equitable remedy within the court's discretion; however, the economic outcome (return of $3,500,000) is identical to the recommended negotiated refund | Moderate
Sophisticated investor defense | Supportive of Lumos's position on the justifiable reliance element, but not dispositive; sophisticated investors may still justifiably rely on specific factual representations within the counterparty's superior knowledge | Supportive but not dispositive

PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGED ATTORNEY WORK PRODUCT

MEMORANDUM

MATTER NO.: 1008-00003

I. EXECUTIVE SUMMARY

II. FACTUAL BACKGROUND

III. LEGAL ANALYSIS

V. CONCLUSION AND RECOMMENDATION

VI. REVIEW AND DISTRIBUTION

Record

Parties

Dates

Amounts